(b)As four phase III trials comparing platinum-based chemotherapy plus PD-1/PD-L1 inhibitor with platinum-based chemotherapy allowed enrollment of patients with PS 0–1 [20–23], there has been no efficacy or safety data of platinum-based chemotherapy plus PD-1/PD-L1 inhibitor in stage IV NSCLC patients with PS 2. The gene discussed is CD274; the disease is non-small cell lung carcinoma.